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Abstract
Novel immune biomarkers could complement the TNM classiﬁcation for nonesmall cell cancer (NSCLC),
improving the prognostic accuracy. The present study evaluated the prognostic signiﬁcance of the immune
checkpoint molecules programmed cell death protein 1 (PD-1) and PD-1 ligand (PD-L1) in 536 patients with
stage I to IIIA NSCLC using an Immunoscore approach. Independently, and in combination, the inﬁltration of
immune cells expressing PD-L1 and PD-1 predicted patient survival, supplementing the TNM classiﬁcation in
each stage.
Introduction: Immune checkpoint inhibitors targeting programmed cell death protein 1 (PD-1) or its ligand, PD-L1,
have gained momentum in the treatment of nonesmall cell lung cancer (NSCLC). However, their prognostic signiﬁ-
cance remains controversial. The present study evaluated the expression of PD-L1 and PD-1 and their potential role in
an Immunoscore, supplementing the TNM classiﬁcation of NSCLC. Materials and Methods: Tissue microarrays
constructed from tumor tissue samples from 2 cohorts of a total of 536 patients (University Hospital of North Norway,
n ¼ 285; Nordland Hospital, n ¼ 251) with primary resected stage I to IIIA NSCLC. PD-L1 and PD-1 were evaluated by
immunohistochemistry in the primary tumor and metastatic lymph node tissue. Results: In univariate analysis, a high
density of PD-L1þ immune cells in the stromal compartment (S-PD-L1) and PD-1þ intraepithelial tumor inﬁltrating
lymphocytes (T-PD-1) was associated with favorable disease-speciﬁc survival (DSS; S-PD-L1, P ¼ .004; T-PD-1, P ¼
.012), both limited to the squamous cell carcinoma histologic subgroup (S-PD-L1, P ¼ .002; T-PD-1, P ¼ .034). A
combined low S-PD-L1 and T-PD-1 was associated with poor survival in all patients (DSS: hazard ratio [HR], 1.81;
95% conﬁdence interval [CI], 1.37-2.40; P < .001) at both centers and for all pathologic stages. In multivariate analysis,
S-PD-L1 and T-PD-1 were independent positive prognostic factors, and combined low scores remained an inde-
pendent prognosticator for poor survival (DSS: HR, 1.72; 95% CI, 1.29-2.28; P < .001; disease-free survival, P ¼ .001;
overall survival, P ¼ .005). Conclusion: Our study identiﬁed S-PD-L1 and T-PD-1 as independent positive prognostic
factors for NSCLC patients. Their combination added signiﬁcant prognostic impact within each pathologic stage and
hence are feasible to include in a TNM Immunoscore.
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The TNM classiﬁcation system is currently the most important
predictor of survival and is an essential guide to treatment decision-
making for nonesmall cell lung cancer (NSCLC), supplemented
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accuracy.1 Accumulating evidence that the immune contexture,
deﬁned as the type, density, location, and organization of immune
cell subtypes, constitutes a major inﬂuence on cancer patient out-
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PD-1 and PD-L1 in a NSCLC Immunoscoreaid in the prognostic assessment of cancer patients. Analysis of the
presence and subtypes of tumor inﬁltrating lymphocytes (TILs) in the
tumor microenvironment adds signiﬁcantly to the prognostic yield of
the TNM classiﬁcation in colorectal4 and breast cancer.5 In colorectal
cancer, the Immunoscore has even surpassed the prognostic impact of
the TNM classiﬁcation. To explore the Immunoscore concept in
NSCLC patients, our group identiﬁed candidate immune markers
(CD8, CD45RO) for an NSCLC TNMeImmunoscore.6-8 In search
of other prognostic markers of immunologic importance that could
potentially contribute to an NSCLC Immunoscore, immune check-
point molecules are of great interest.
Immune checkpoint pathways induce costimulatory and inhibitory
signals crucial for regulating the physiologic T cell immune response
and maintaining self-tolerance.9 Activation of the programmed cell
death protein 1 (PD-1) pathway mediates inhibitory signals in T cells
in the peripheral effector phase of T-cell activation.9 PD-1 is
expressed by activated T cells, B cells, natural killer T cells, and
myeloid cells and is often highly expressed by TILs. PD-1 ligand 1
(PD-L1) is expressed by a wide range of hematopoietic and non-
hematopoietic cell types.10 Also, PD-L1 is frequently highly expressed
by human cancer cells, induced intrinsically by oncogenic pathways
or extrinsically by inﬂammatory mediators, of which interferon-g is
the most potent.11 Ligation of PD-L1 with PD-1 mediates sup-
pression of T cell function, differentiation, and survival.11 Termed
“adaptive immune resistance,” increased tumor PD-L1 expression as a
response to the secretion of cytokines from activated TILs is
considered a major mechanism of immune evasion in cancer.9
Immune checkpoint inhibitors targeting the PD-1 pathway have
demonstrated impressive clinical beneﬁt in several cancers,
including NSCLC, although for a limited fraction of patients.12
This has fueled great interest in the potential prognostic and pre-
dictive value of PD-L1 and PD-1 expression. Although some studies
have reported high PD-L1 expression in tumor cells or TILs to be
predictive of the response to PD-1 pathway inhibition,13-16 it has
not proved adequately reliable as a single biomarker.17,18 The results
regarding its prognostic effects in NSCLC are conﬂicting.19 Also,
the variability in assays and deﬁnitions of biomarker positivity have
deﬁnitely challenged its validity as a biomarker.20 Few studies have
reported the prognostic effect of stromal expression of PD-L1 and
PD-1þ TILs. To the best of our knowledge, no study has compared
its expression in primary tumors and lymph node metastases. To
assess their prognostic impact and potential as Immunoscore
candidate markers, we analyzed the expression of PD-1 and PD-L1
in the tumor epithelium and stromal compartments of 536 primary
resected tumors from patients with stage I to IIIA NSCLC and in
142 matched metastatic lymph nodes.
Materials and Methods
Patients and Clinical Samples
Primary tumor tissue specimens from patients who had undergone
radical resection for NSCLC pathologic stage I to IIIA at the Uni-
versityHospital ofNorthNorway (UNN) and theNordlandHospital
(NH) from 1990 through 2010 were retrospectively collected for the
present study. The tumors were staged according to the current In-
ternational Union Against Cancer TNM classiﬁcation, seventh edi-
tion,21 and histologically classiﬁed according to the 2011 Worldnical Lung Cancer Month 2016Health Organization guidelines on the classiﬁcation of lung cancer.22
According to the hospital pathologic databases, 633 cases of NSCLC
were diagnosed during the study period. Of the 633 patients, 97 were
excluded because of (1) radiotherapy or chemotherapy before surgery
(n ¼ 15); (2) other malignancy within 5 years before the NSCLC
diagnosis (n¼ 39); (3) inadequate parafﬁn-embedded formalin-ﬁxed
tissue blocks available (n¼ 25); or (4) the presence of adenocarcinoma
in situ, which, before 2011 was classiﬁed as bronchioloalveolar
carcinoma  3 cm (n ¼ 18).23 Thus, 536 patients with complete
medical records and adequate parafﬁn-embedded tissue blocks
available were eligible, including 142 patients with available lymph
node specimens of the 172 patients with node-positive disease. The
present report includes follow-up data to October 1, 2013. The
median follow-up time of the survivors was 86months (range, 34-267
months). The Norwegian Data Protection Authority and the
Regional Committee for Medical and Health Research Ethics
approved the present study (protocol ID, 2011/2503) and waived the
need for patient consent. The reporting of the clinicopathologic
variables, survival data, and biomarker expression was conducted in
accordance with the REMARK (reporting recommendations for tu-
mor marker prognostic studies) guidelines.24
Microarray Construction
Two pathologists histologically reviewed all the tissue specimens.
The most representative areas of viable neoplastic epithelial cells and
tumor stroma in the primary tumors and matched positive lymph
nodes (LNs) were carefully selected for the tissue microarrays
(TMAs). The TMAs were assembled using a tissue-arraying in-
strument (Beecher Instruments, Silver Springs, MD). The detailed
method has been previously reported.25 In brief, we used a 0.6-mm
diameter stylet, and the study specimens were routinely sampled
with 2 replicate core samples from different areas of the tumor
epithelium and 2 from the tumor stroma in primary tumors and
metastatic LNs. Multiple 4-mm sections were cut using a Microm
microtome (HM355S; Thermo Fisher Scientiﬁc Life Sciences,
Waltham, MA) and stained using speciﬁc antibodies for immuno-
histochemistry (IHC) analysis.
IHC Analysis
For analysis of PD-L1 expression with IHC, we used the following
antibodies: mouse monoclonal (catalog no. MAB1561; R&D Sys-
tems, Minneapolis, MN), rabbit polyclonal (catalog no. ab58810;
Abcam, Cambridge, UK), and rabbit monoclonal (catalog no. 13684;
clone, E1L3N; Cell Signaling Technology, Danvers, MA). For
analysis of PD-1 expression with IHC, mouse monoclonal antibody
(catalog no. ab52587; clone, NAT105; Abcam) was applied.
The speciﬁcity of the antibodies was veriﬁed by staining multi-
organ TMAs as positive and negative tissue controls and by corre-
sponding transfectant plasmid cell lysates (see Antibody Validation).
The positive tissue controls were tonsil for PD-1 and placenta for
PD-L1. The negative tissue controls were samples of normal brain
and ventricle for both PD-1 and PD-L1. These antibodies fulﬁlled
the standards for evaluation in our lung cancer population: PD-L1
(clone E1L3N) and PD1 (clone NAT105).
IHC analysis was performed using the Discovery-Ultra immu-
nostainer (Ventana Medical Systems, Tucson, AZ). The slides were
Erna-Elise Paulsen et aldeparafﬁnized in three 8-minute cycles. For on-board antigen
retrieval, PD-L1 and PD-1 were incubated with CC1 for 64 and 32
minutes, respectively. Endogenous peroxidase was blocked by Dis-
covery inhibitor (catalog no. 760-4840; Ventana Medical Systems)
for 8 minutes for both antibodies. The PD-L1 primary antibody in 1/
25 dilution was loaded, and the slides were incubated for 32 minutes
at 37C. The slides were developed using UltraMap anti-rabbit
horseradish peroxidase (HRP; catalog no. 760-4315) for 20 mi-
nutes, followed by 8 minutes of HRP ampliﬁcation, and detection
using ChromoMap DAB (catalog no. 760-159; Ventana Medical
Systems). The PD-1 primary antibody in 1/50 dilution was incubated
for 60 minutes at 37C. Next, OmniMap anti-mouse HRP (catalog
no. 760-4310) was applied for 16 minutes, followed by 16 minutes of
HRP ampliﬁcation. The primary antibodies were visualized using a
purple detection kit (catalog no. 760-229) with a 32-minute incu-
bation time. Finally, to detect the nuclei, the slides were counter-
stained with hematoxylin II reagent (Ventana Medical Systems) for
32 minutes, followed by a bluing reagent for 8 minutes. The slides
were then dehydrated, cleared, and mounted using routine process-
ing. Control staining with an isotype-matched antibody by omission
of the primary antibody was also performed for each antibody. For
each antibody, staining was performed as a single experiment.
Antibody Validation
Transient overexpressed human HEK293T cell lysates were used
for PD-L1 (catalog no. LY415473), PD-1 (catalog no. LY401555),
and HEK293 (catalog no. LY500001/negative control; all from
OriGene Technologies, Rockville, MD). They were incubated with
2  sodium dodecyl sulfate sample buffer (OriGene Technologies)
for 10 minutes at 100C. Equal amounts of protein lysates were
resolved onto a 4% to 12% Bis-Tris gel (catalog no. NP0322; Life
Technologies, Carlsbad, CA). The resolved proteins were transferred
onto an Odyssey nitrocellulose membrane (catalog no. 926-31092;
LI-COR Biosciences, Lincoln, NE), and the membrane was subse-
quently blocked for 1 hour at room temperature using the Odyssey
blocking buffer (catalog no. 927-40000; LI-COR Biosciences). PD-
L1 antibody in a 1/1000 dilution and PD-1 antibody in a 1/50
dilution were applied, and the membrane was incubated overnight at
4C. IRDye 800CW secondary antibodies for PD-L1 (catalog no.
926-32213; LI-COR Biosciences) and PD-1 (catalog no. 926-32212;
LI-COR Biosciences) in 1/10,000 dilution were incubated for 1 hour
at room temperature. Rabbit anti-actin (catalog no. A2066; Sigma-
Aldrich, St. Louis, MO), 1:1000, was used as the internal control,
and all lanes showed 42-kDa molecular weight protein load
(Supplemental Figure 1; online version). Between antibody in-
cubations, the membrane was washed 3 times for 5 minutes each in
Tris-buffered saline containing 0.05% Tween 20 (Sigma-Aldrich).
MagicMark XP Western Protein Standard (catalog no. LC5603;
Invitrogen, Carlsbad, CA) and SeeBlue Plus2 prestained standard
(catalog no. LC5925; Invitrogen) were used as molecular weight
ladders. The most prominent bands represent the observed molecular
weight of the detected protein, which corresponded intimately with
the predicted weight provided by the manufacturer.
IHC Scoring
The samples were anonymized and independently scored by 2 of
us (PD-L1: T.K.K. and E.-E.P.; PD-1: M.R.K. and E.-E.P.), underthe supervision of an experienced pathologist (E.R.), who estab-
lished a semiquantitative score for each marker. When assessing a
given core, the observers were blinded to the other’s ﬁndings, the
clinical variables, and the outcomes.
The NSCLC tumor stroma consists mainly of immune cells of
myeloid and lymphoid origin, in addition to basement membranes,
ﬁbroblasts, extracellular matrix, and vasculature. The tumor
epithelial and stromal compartments were scored separately.
PD-L1 staining was typically cytoplasmatic, with a variably
strong component of membranous staining. In general, the staining
intensity of PD-L1 in tumor epithelial cells (T-PD-L1) was rela-
tively homogenous, although in some cases, and more commonly
in solid tumor aggregates, the intensity was stronger in the
tumorestroma interface. The intensity of T-PD-L1 was scored as 0,
no staining; 1, weak; 2, moderate; and 3, strong.
In the stromal compartment, PD-L1 staining (S-PD-L1) was
predominantly found in cells morphologically consistent with im-
mune cells, with homogenous, moderate to strong intensity. The
percentage of stromal PD-L1þ cells compared with the total
number of nucleated cells (density) was scored as 0, absent; 1, 1% to
49%; 2, 50% to 75%; or 3, > 75%.
The PD-1 antibody stained cells morphologically consistent with
TILs, with homogenous intensity. The percentage of intraepithelial
PD-1þ TILs completely enclosed by tumor epithelial cells compared
with the total number of nucleated TILs (density) in the tumor
epithelial compartment (T-PD-1) was scored as 0, absent; 1, 1% to
9%; 2, 10% to 50%; or 3, > 50%. In the stromal compartment (S-
PD-1), it was scored as 0, absent; 1, 1% to 24%; 2, 25% to 50%; or
3, > 50%. Scoring of the density of CD8þ and CD45ROþ TILs
has been previously reported.8 Identical scoring approaches were
used in the primary tumors and metastatic LNs for T-PD-L1 and T-
PD-1. However, the stromal component of metastatic tissue in LNs
is difﬁcult to discern from LN tissue and, therefore, was not scored.
Two cores were sampled from each compartment (tumor
epithelial and stromal) and scored by 2 of us. Both cores from
primary tumors were missing in 5% to 6% of cases, and 1 core was
missing in 3% to 7% of cases. For metastatic LN tissue, both cores
were missing in 12% to 15%, and 1 core was missing in 12% to
18% of cases. The mean value of the 4 or 2 (if 1 TMA core was
missing) scores available from each patient was used as the basis for
dichotomization of the patients’ scores into categories of high and
low. All possible cutoff thresholds were tested. For each marker, the
cutoff chosen for dichotomization was the one yielding the mini-
mum P value when analyzing the association between each marker
with disease-speciﬁc survival (DSS) in primary tumors, keeping the
categories balanced in size (close to the mean value). Accordingly, a
high score was deﬁned as follows (mean value of single scores
provided in parentheses): T-PD-L1 > 1.25 (1.12), S-PD-L1 > 1.5
(1.45), T-PD-1 > 0.25 (0.68), S-PD-1 > 1 (1.21), S-CD8 > 1.5
(1.55), and T-CD45RO > 0.5 (0.66). We applied the same cutoffs
for the LN metastases. IHC scoring of PD-L1 and PD-1 in the
primary tumor is illustrated in Figure 1. IHC scoring of the met-
astatic LNs is presented in Supplemental Figure 2 (online version).
Statistical Analysis
All statistical analyses were performed using the SPSS, version 22
(SPSS, Chicago, IL). The IHC scores from each observer wereClinical Lung Cancer Month 2016 - 3
Figure 1 Programmed Cell Death Protein 1 (PD-1) and PD-1 Ligand (PD-L1) Immunohistochemical Analysis in Primary Tumors.
Immunohistochemical Analysis of NoneSmall Cell Lung Cancer Representing Different Scores for Tumor Cell and Stromal
Expression in Primary Tumors. (A) Low Intraepithelial PD-1D Tumor Inﬁltrating Lymphocytes (TILs) (T-PD-1) Score
(Squamous Cell Carcinoma [SCC]). (B) High T-PD-1 Score (SCC). (C) Low Stromal PD1D TILs (S-PD-1) Score (SCC). (D) High
S-PD-1 Score (Adenocarcinoma [ADC]). (E) PD-1D Tissue Control (Tonsil). (F) Low Intraepithelial PD-L1 (T-PD-L1) Score
(SCC). (G) High T-PD-L1 Score (SCC). (H) Low Stromal PD-L1D Immune Cell (S-PD-L1) Score (SCC). (I) High S-PD-L1 Score
(ADC). (J) PD-L1D Tissue Control (Placenta). Original Magniﬁcation320. In Most Tumor Cores and in Some Stromal Cores, a
Mixture of Stromal Cells and Tumor Cells Was Found. Using Morphologic Criteria, We Scored Intraepithelial Cells Only if
Tumor Tissue Was Present and Stromal Cells Only in Stromal Tissue
PD-1 and PD-L1 in a NSCLC Immunoscore
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Table 1 Clinicopathologic Variables as Predictors of Disease-Speciﬁc Survival in 536 NSCLC Patients (Univariate Analyses; Log-Rank Test, Unadjusted Cox Proportional HRs)
Variable
All Patients SCC Patients ADC Patients
n (%)
5-Year
DSS (%)
Median
DSS (mo) HR (95% CI) P Value n (%)
5-Year
DSS (%)
Median
DSS (mo) HR (95% CI) P Value n (%)
5-Year
DSS (%)
Median
DSS (mo) HR (95% CI) P Value
Age (years) .711 .654 .505
65 227 (42) 57 127 1 106 (37) 64 235 1 102 (51) 48 54 1
>65 309 (58) 58 NA 0.95 (0.73-1.24) 183 (63) 66 NA 0.91 (0.61-1.36) 99 (49) 49 57 0.87 (0.59-1.3)
Sex .026a .108 .050a
Female 170 (32) 63 190 1 73 (25) 73 NA 1 83 (41) 56 190 1
Male 366 (68) 55 88 1.4 (1.06-1.84) 216 (75) 63 235 1.49 (0.96-2.31) 118 (59) 43 51 1.5 (1.01-2.23)
ECOG PS .015a .158 .003a
0 310 (58) 62 235 1 158 (55) 69 235 1 122 (61) 56 NA 1
1 190 (35) 52 71 1.45 (1.09-1.93) 110 (38) 61 114 1.47 (0.97-2.23) 67 (33) 40 50 1.57 (1.02-2.4)
2 36 (7) 48 36 1.61 (0.83-3.09) 21 (7) 67 NA 1.08 (0.45-2.6) 12 (6) 17 25 3.25 (0.96-11.03)
Smoking .039a .19 .68
Never 17 (3) 44 20 1 7 (2) 50 19 1 9 (5) 44 21 1
Previous 342 (64) 62 235 0.56 (0.25-1.24) 182 (63) 69 235 0.58 (0.14-2.37) 125 (62) 50 68 0.69 (0.26-1.84)
Present 177 (33) 51 71 0.75 (0.33-1.7) 100 (35) 60 114 0.82 (0.2-3.41) 67 (33) 45 57 0.73 (0.27-1.99)
Weight loss .961 .689 .536
<10% 480 (90) 58 127 1 257 (89) 66 235 1 184 (92) 49 57 1
10% 55 (10) 59 NA 0.99 (0.63-1.56) 32 (11) 62 NA 1.14 (0.57-2.28) 17 (8) 40 47 1.24 (0.59-2.63)
Surgical procedure <.001a <.001a <.001a
Wedge or lobectomy 394 (74) 63 190 1 197 (68) 72 235 1 161 (80) 54 104 1
Pneumonectomy 142 (26) 42 30 1.98 (1.43-2.74) 92 (32) 50 35 1.99 (1.28-3.09) 40 (20) 25 24 2.66 (1.46-4.84)
Surgical margins .129 .252 .018a
Free 489 (91) 59 190 1 257 (89) 67 235 1 189 (94) 50 68 1
Not free 47 (9) 47 57 1.39 (0.85-2.29) 32 (11) 57 114 1.39 (0.73-2.63) 12 (6) 0 35 2.33 (0.81-6.69)
T stage <.001a <.001a <.001a
1 168 (31) 72 235 1 83 (29) 78 235 1 74 (37) 67 190 1
2 265 (49) 57 91 1.74 (1.3-2.32) 147 (51) 66 NA 1.88 (1.22-2.89) 94 (47) 43 47 1.94 (1.27-2.95)
3 97 (18) 36 30 2.84 (1.87-4.31) 56 (19) 46 33 2.93 (1.62-5.31) 31 (15) 16 25 3.48 (1.76-6.9)
4 6 (0) 20 15 4.89 (0.89-26.9) 3 (1) 0 10 17.41
(0.22-1371.77)
2 (1) 50 13 1.76 (0.23-13.27)
N stage <.001a <.001a <.001a
0 364 (68) 69 235 1 198 (69) 77 235 1 133 (66) 60 190 1
1 118 (22) 36 35 2.76 (1.93-3.94) 73 (25) 45 35 3.26 (1.99-5.35) 39 (19) 25 30 2.41 (1.38-4.2)
2 54 (10) 21 19 4.23 (2.43-7.37) 18 (6) 18 13 7.12 (2.44-20.77) 29 (15) 23 24 2.88 (1.42-5.82)
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Table 1 Continued
Variable
All Patients SCC Patients ADC Patients
n (%)
5-Year
DSS (%)
Median
DSS (mo) HR (95% CI) P Value n (%)
5-Year
DSS (%)
Median
DSS (mo) HR (95% CI) P Value n (%)
5-Year
DSS (%)
Median
DSS (mo) HR (95% CI) P Value
Pathologic stage <.001a <.001a <.001a
I 256 (48) 72 235 1 127 (44) 82 235 1 105 (52) 65 190 1
II 194 (36) 53 84 1.89 (1.42-2.51) 126 (44) 60 114 2.5 (1.66-3.77) 56 (28) 34 43 2.07 (1.3-3.28)
IIIA 86 (16) 20 17 4.58 (2.87-7.32) 36 (12) 23 15 7.15 (3.23-15.84) 40 (20) 16 24 3.37 (1.8-6.33)
Histologic type .040a
SCC 289 (54) 65 235 1
ADC 201 (37) 48 57 1.43 (1.08-1.89)
LCC 46 (9) 50 83 1.29 (0.8-2.08)
Differentiation <.001a .033a .006a
Poor 231 (43) 49 51 1 104 (36) 57 84 1 81 (40) 38 43 1
Moderate 240 (45) 63 190 0.67 (0.5-0.89) 155 (54) 70 235 0.63 (0.41-0.97) 85 (42) 50 68 0.69 (0.44-1.07)
Well 65 (12) 70 NA 0.44 (0.29-0.66) 30 (10) 72 NA 0.47 (0.24-0.94) 35 (18) 69 NA 0.36 (0.21-0.63)
Vascular inﬁltration <.001a .029a .012a
No 437 (82) 62 235 1 231 (80) 69 235 1 172 (86) 52 71 1
Yes 97 (18) 38 35 1.89 (1.29-2.78) 58 (20) 53 71 1.65 (0.97-2.82) 27 (13) 26 27 1.9 (1-3.62)
Missing 2 (0) 2 (1)
Abbreviations: ADC ¼ adenocarcinoma; CI ¼ conﬁdence interval; DSS ¼ disease-speciﬁc survival; ECOG PS ¼ Eastern Cooperative Oncology Group performance status; HR ¼ hazard ratio; LCC ¼ large cell carcinoma; NA ¼ not applicable; NSCLC ¼ nonesmall-cell lung
cancer; SCC ¼ squamous cell carcinoma.
aStatistically signiﬁcant.
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Table 2 Prognostic Effect of Tumor Epithelial and Stromal PD-1 and PD-L1 Expression in Primary Tumors and Metastatic Lymph Nodes on Disease-Speciﬁc Survival (Univariate Analyses;
Log-Rank Test, Unadjusted Cox Proportional HRs)
Variable
All Patients SCC ADC
n (%)
5-Year
DSS (%)
Median
DSS (mo) HR (95% CI) P Value n (%)
5-Year
DSS (%)
Median
DSS (mo) HR (95% CI) P Value n (%)
5-Year
DSS (%)
Median
DSS (mo) HR (95% CI) P Value
S-PD-L1 .004a .002a .501
High 182 (34) 67 235 1.00 105 (36) 80 NR 1.00 67 (33) 50 57 1.00
Low 323 (60) 53 73 1.55 (1.15-2.1) 173 (60) 57 235 2.09 (1.31-3.32) 120 (60) 47 57 0.75 (0.10-1.79)
Missing 31 (6) 11 (4) 14 (7)
T-PD-L1 .313 .037a .632
High 130 (24) 63 190 1.00 64 (22) 79 235 1.00 55 (27) 47 47 1.00
Low 373 (70) 56 104 1.19 (0.85-1.63) 211 (73) 63 NR 1.79 (1.03-3.11) 131 (65) 48 57 0.90 (0.58-1.40)
Missing 33 (6) 14 (5) 15 (8)
Nþ LN T-PD-L1 .773 .674 .544
High 36 (25) 32 21 1.00 15 (20) 13 40 1.00 17 (29) 25 37 1.00
Low 84 (59) 31 24 0.93 (0.57-1.52) 47 (64) 44 25 0.85 (0.41-1.79) 30 (52) 13 24 1.25 (0.61-2.59)
Missing 23 (16) 12 (16) 11 (19)
S-PD-1 .080 .182 .251
High 253 (47) 62 253 1.00 134 (46) 72 253 1.00 98 (49) 52 73 1.00
Low 253 (47) 53 91 1.28 (0.97-1.68) 142 (49) 60 NR 1.32 (0.88-1.99) 90 (45) 44 50 1.27 (0.84-1.91)
Missing 30 (6) 13 (5) 13 (6)
T-PD-1 .012a .034a .281
High 282 (53) 63 235 1.00 155 (54) 73 235 1.00 103 (51) 52 88 1.00
Low 225 (42) 51 64 1.42 (1.08-1.86) 122 (42) 57 NR 1.55 (1.03-2.32) 85 (42) 43 52 1.25 (0.83-1.88)
Missing 29 (5) 12 (4) 13 (7)
Nþ LN T-PD-1 .570 .168 .781
High 38 (27) 34 27 1.00 14 (19) 64 105 1.00 20 (34) 16 13 1.00
Low 87 (61) 31 21 1.15 (0.70-1.90) 48 (65) 42 33 1.93 (0.74-5.00) 34 (59) 15 23 0.91 (0.47-1.76)
Missing 17 (12) 12 (16) 4 (7)
S-PD-L1 þ T-PD-1 <.001a <.001a .045a
Other 339 (63) 63 235 1.00 195 (68) 74 235 1.00 117 (58) 54 189 1.00
Low þ low 157 (29) 43 43 1.81 (1.37-2.40) 78 (27) 47 37 2.06 (1.36-3.13) 68 (34) 38 50 1.52 (1.01-2.31)
Missing 40 (8) 16 (5) 16 (8)
Abbreviations: ADC ¼ adenocarcinoma; CI ¼ conﬁdence interval; DSS ¼ disease-speciﬁc survival; HR ¼ hazard ratio; NA ¼ not applicable; Nþ LN ¼ metastatic lymph node; NR ¼ not reached; NSCLC ¼ nonesmall-cell lung cancer; PD-1 ¼ programmed cell death protein 1;
PD-L1 ¼ PD-1 ligand; S ¼ stromal; SCC ¼ squamous cell carcinoma; T ¼ tumor.
aStatistically signiﬁcant.
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Figure 2 Survival Curves. Disease-Speciﬁc Survival Curves Are
Shown According to Intraepithelial Programmed Cell
Death Protein 1-Positive (PD-1D) Tumor Inﬁltrating
Lymphocytes (TILs) (T-PD-1) (A), Stromal PD-1D TILs
(S-PD-1) (B), Intraepithelial PD-L1 (T-PD-L1) (C), and
Stromal PD-L1D Immune Cells (S-PD-L1) (D) in Primary
Tissue for All Patients
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8 - Clicompared for interobserver reliability using a 2-way random effects
model with absolute agreement deﬁnition, yielding an intraclass
correlation coefﬁcient (reliability coefﬁcient) and Cohen’s kappa.
DSS, disease-free survival (DFS), and overall survival (OS) were
deﬁned as the time from surgery to lung cancer death, ﬁrst lung
cancer relapse, and death from any cause, respectively.
The c2 test or Fischer’s exact test was used to examine the as-
sociation between molecular marker expression and various clini-
copathologic parameters. Spearman’s rank correlation coefﬁcient
was used to examine the associations among the markers’ expres-
sion. Univariate analysis of survival according to each immune
marker was visualized using the Kaplan-Meier method, and sta-
tistically signiﬁcant differences between survival curves were
assessed using the log-rank test. For univariate analyses, unad-
justed Cox proportional hazard ratios (HRs) were calculated.
Multivariate analysis was performed using the Cox proportional
hazards model, testing the simultaneous inﬂuence on survival of all
relevant, by expert opinion, covariates found to be signiﬁcant on
the univariate analyses. All clinicopathologic variables signiﬁcant
in the initial multivariate analysis were included in the multivariate
analyses, including the immunologic markers assessed in the pre-
sent study. The backward conditional method was used for model
ﬁtting. The probability for stepwise entry and removal was set at
.05 and .10, respectively. P values < .05 were considered statis-
tically signiﬁcant.
Results
Patient Characteristics
The demographic, clinical, and histopathologic variables are lis-
ted in Table 1. The median age was 67 years (range, 28-85 years),
and 68% of the patients were men. Because of LN metastasis or
nonradical surgical margins, 76 patients (14%) received post-
operative radiotherapy. After its introduction into the Norwegian
national guidelines in 2005 (stage II-IIIA disease), 43 patients (8%)
received adjuvant therapy. Of the 172 patients with Nþ disease, 91
were diagnosed with squamous cell carcinoma (SCC), 68 with
adenocarcinoma (ADC), and 13 with large cell carcinoma.
Correlations Between PD-1/PD-L1 and Clinicopathologic
Variables, Interobserver Reliability, and Between-Core
Heterogeneity
No signiﬁcant associations were found between the expression of
PD-L1 or PD-1 and age, sex, Eastern Cooperative Oncology Group
status, smoking, N status, pathologic stage, histologic subgroup, or
vascular inﬁltration. The level of heterogeneity was low (assessed
using intraclass correlations), and the agreement between the 2 cores
sampled from 1 tumor was greater for markers analyzed in primary
tumor nests (T-PD-L1, 0.844; T-PD-1, 0.805) than in primary
tumor stroma (S-PD-L1, 0.792; S-PD-1, 0.726). A similar tendency
was found in the metastatic LNs (LN T-PD-L1, 0.917; LN T-PD-
1, 0.797). Extensive correlations were found between the mean
scores of PD-L1 and PD-1 in the intraepithelial and stromal com-
partments. Between the primary tumor and LN tissue scores, we
found a signiﬁcant correlation only for T-PD-1 (Supplemental
Table 1; online version). The between-scorer agreement was
excellent, with an intraclass correlation > 0.83 for all markers
(Supplemental Table 2; online version).nical Lung Cancer Month 2016
Erna-Elise Paulsen et alUnivariate Analysis
The results of the univariate analyses of the prognostic impact
regarding stromal and tumor PD-1 and PD-L1 expression on DSS
are presented in Table 2 and Figure 2. For S-PD-L1 and T-PD-1,
several different thresholds for high and low expression resulted in a
signiﬁcant association with DSS. The results were largely similar for
the DFS and OS endpoints (Supplemental Table 3; online version).
In the entire patient material, a low density of PD-L1þ cells in
the stromal compartment (S-PD-L1) was associated with unfavor-
able DSS (HR, 1.55; 95% conﬁdence interval [CI], 1.15-2.10; P ¼
.004). A low density of intraepithelial PD-1þ immune cells (T-PD-
1) was also signiﬁcantly and negatively associated with DSS (HR,
1.42; 95% CI, 1.08-1.86; P ¼ .012).
When assessing the outcome by histologic subgroup, low S-PD-
L1 was signiﬁcantly associated with DSS (HR, 2.09; 95% CI, 1.31-
3.32; P ¼ .002) in the SCC patient subgroup in both cohorts
(UNN, P ¼ .017; and NH, P ¼ .033). Also, low tumor epithelial
expression of PD-L1 (T-PD-L1; HR, 1.79; 95% CI, 1.03-3.11;
P ¼ .037) and PD-1 (T-PD-1; HR, 1.55; 95% CI, 1.03-2.32; P ¼
.034) had a signiﬁcant negative prognostic impact on DSS in SCC
patients. PD-L1 or PD-1 status was not associated with survival for
patients with large cell carcinoma or ADC.Figure 3 From TNM to TNM-I. Disease-Speciﬁc Survival (DSS) Curve
Programmed Cell Death Protein (PD) Immunoscore Accord
Inﬁltrating Lymphocyte (T-PD-1) and Stromal PD-L1 (S-PD
Immunoscore Resulted in a TNM Immunoscore Table of 5-
Pathologic Stage (Pstage). Furthermore, Patients Were Gro
10%, 10%-40%, 40%-70%, > 70%), and the Resulting SurMetastatic LNs
No signiﬁcant associations were found between the expression
of PD-L1 and PD-1 in the metastatic LNs and survival (DSS,
DFS, or OS; Table 2; Supplemental Table 1; online version).
The frequency of high T-PD-L1 was 29% in both primary tu-
mors and metastatic LNs. Nearly 69% displayed identical scores
in the primary tumor and LN metastasis, 16% had a high score
in the primary tissue and a low score in the LNs, and 15% had
the opposite. The frequency of T-PD-1þ TILs was lower in
metastatic LNs (30%) than in primary tumors (56%; P < .001);
53% maintained the score in the metastatic LNs, 38% had a high
score in the primary tissue only, and 9% in the metastatic
LNs only.
PD Immunoscore
Combining the scores of the 2 variables with the strongest
prognostic impact for all patients in the univariate analyses, S-PD-
L1 and T-PD-1, allowed for stratiﬁcation of patients with low
scores for both markers compared with all other score combina-
tions (PD Immunoscore; Figure 3). This combination yielded a
highly signiﬁcant negative association of “low þ low” scores with
DSS in the entire patient material (HR, 1.81; 95% CI, 1.37-2.40;s of All Patients According to (A) Pathologic Stage (TNM) and (B)
ing to the Combination of the PD-1D Intraepithelial Tumor
-L1) Score. The Combination of Pathologic Stage and PD
Year DSS (C), Adding Signiﬁcant Prognostic Impact Across Each
uped by 5-Year Survival According to the TNM Immunoscore (<
vival Curves (D) Illustrate the Increased Stratiﬁcation
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Table 3 Results of Cox Regression Analysis Summarizing Signiﬁcant Independent Prognostic Factors for Disease-Speciﬁc Survival
Variable
All Patients SCC ADC
HR (95% CI) P Value HR (95% CI) P Value HR (95% CI) P Value
Clinicopathologic variablesa
Pathologic stage <.001b,c <.001b,c <.001b,c
I 1.00 1.00 1.00
II 1.79 (1.31-2.46) <.001b 2.49 (1.53-4.06) <.001b 2.20 (1.37-3.53) .001b
IIIA 4.08 (2.83-5.89) <.001b 7.38 (4.17-13.07) <.001b 3.33 (1.94-5.72) <.001b
Histologic type .003b,c
SCC 1.00
ADC 1.62 (1.21-2.19) .001b
LCC 1.00 (0.60-1.67) .996
Vascular inﬁltration
No vs. yes 1.79 (1.29-2.50) .001b 1.51 (0.95-2.41) .081 1.72 (1.01-2.94) .048b
Differentiation .006b,c .303c .098c
Well 1.00 1.00 1.00
Moderate 1.75 (1.02-3.01) .042b 1.31 (0.59-2.89) .201 1.99 (0.98-4.03)
Poor 2.32 (1.35-3.99) .001b 1.69 (0.76-3.78) .507 2.13 (1.06-4.26)
Sex
Female vs. male 1.68 (1.24-2.29) .001b NE 1.64 (1.07-2.52) .023b
ECOG PS .005b,c NE .003b,c
0 1.00 1.00
1 1.54 (1.16-2.03) .003b 1.64 (1.08-2.50) .021
2 1.78 (0.99-3.18) .052 3.59 (1.58-8.16) .002
Smoking .013b,c NE NE
Never 1.00
Present 0.36 (0.18-0.71) .003b
Former 0.41 (0.20-0.82) .012b
Surgical margins
Free vs. not free NE NE 1.42 (0.67-2.93) .362
PD variables assessed in separate modelsd
T-PD-L1
High vs. low 1.72 (0.99-3.00) .055 1.68 (0.97-2.92) .066 1.05 (0.66-1.67) .842
S-PD-L1
High vs. low 1.47 (1.08-1.97) .014 2.16 (1.36-3.44) .001 1.16 (0.75-1.79) .517
T-PD-1
High vs. low 1.48 (1.12-1.96) .005b 1.71 (1.13-2.58) .011b 1.33 (0.88-1.02) .173
S-PD-L1 þ T-PD-1
Other scores vs. low þ low 1.72 (1.29-2.28) <.001b 2.14 (1.41-3.26) <.001b 1.52 (1.00-2.32) .049b
PD variables assessed in same modeld
S-PD-L1a
High vs. low 1.41 (1.03-1.93) .031b 2.05 (1.28-3.3) .003b 1.04 (0.66-1.65) .853
T-PD-1a
High vs. low 1.39 (1.04-1.85) .025b 1.55 (1.03-2.35) .038b 1.39 (0.89-2.15) .145
PD Immunoscore assessed with
S-CD8 and T-CD45ROd
S-PD-L1 þ T-PD-1a
Other scores vs. low þ low 1.48 (1.10-2.00) .010b 1.57 (1.00-2.46) .049b 1.52 (1.00-2.32) .049b
PD-1 and PD-L1 in a NSCLC Immunoscore
10 -P < .001) both centers (UNN, P ¼ .005; NH, P ¼ .001), and all
pathologic stages (I, P ¼ .022; II, P ¼ .009; IIIA, P ¼ .026) and
for DFS (P < .001) and OS (P ¼ .002).Clinical Lung Cancer Month 2016Although the PD Immunoscore was marginally signiﬁcant for
DSS in ADC (P ¼ .045), the prognostic impact for SCC patients
was strong (DSS: HR, 2.06; 95% CI, 1.36-3.13; P < .001) and
Table 3 Continued
Variable
All Patients SCC ADC
HR (95% CI) P Value HR (95% CI) P Value HR (95% CI) P Value
S-CD8a
High vs. low 1.54 (1.15-2.08) .004b 1.93 (1.24-2.99) .004b 1.20 (0.76-1.89) .435
T-CD45ROa
High vs. low 1.36 (0.99-1.87) .060 1.78 (1.13-2.79) .012b 0.593 (0.51-1.47) .593
Abbreviations: ADC ¼ adenocarcinoma; CI ¼ conﬁdence interval; HR ¼ hazard ratio; PD-1 ¼ programmed cell death protein 1; PD-L1 ¼ PD-1 ligand; S ¼ stromal; SCC ¼ squamous cell
carcinoma; T ¼ tumor.
aIn the same model.
bStatistically signiﬁcant.
cOverall signiﬁcance as a prognostic factor.
dAll clinicopathologic covariates signiﬁcant on multivariate analysis were included in each model.
Erna-Elise Paulsen et alwas present for the other survival endpoints (DFS, P < .001; OS,
P ¼ .019) and conﬁrmed at both centers (UNN, P ¼ .004; NH,
P ¼ .042).
Multivariate Analysis
The results from the multivariate Cox regression analysis are
presented in Table 3. Assessed as separate markers included in the
same model, both T-PD-1 and S-PD-L1 had an independent
prognostic effect on DSS (S-PD-L1: HR, 1.41; 95% CI, 1.03-1.93;
P ¼ .031; T-PD-1: HR, 1.39; 95% CI, 1.04-1.85; P ¼ .025) in the
total material. In the SCC patient subgroup, the prognostic effect of
S-PD-L1 (HR, 2.05; 95% CI, 1.28-3.30; P ¼ .003) surpassed the
effect of T-PD-1 (HR, 1.55; 95% CI, 1.03-2.35; P ¼ .038).
The PD Immunoscore yielded a signiﬁcant independent prog-
nostic effect for all patients for DSS, DFS, and OS (HR, 1.72
[Table 3]; HR, 1.57 and 1.36 [Supplemental Table 4; online
version]; P < .001 for all). This ﬁnding was enhanced in the SCC
patient subgroup for all endpoints. In contrast, for the ADC patients,
a trend was found for DSS and OS. When adjusted for S-CD8 and
T-CD45RO, the “low þ low” PD Immunoscore remained an in-
dependent prognostic factor for all the patients (HR, 1.48; 95% CI,
1.10-2.00; P ¼ .010) in both histologic subgroups: SCC (HR, 1.57;
P ¼ .049) and ADC (HR, 1.52; P ¼ .049; univariate analyses of
S-CD8 and T-CD45RO; Supplemental Table 5; online version).
Discussion
In our large, unselected patient material of surgically resected
stage I to IIIA NSCLC, we demonstrated an independent negative
prognostic effect of low stromal PD-L1þ immune cells (S-PD-L1)
and of PD-1þ TILs inﬁltrating the tumor epithelial compartment
(T-PD-1) in primary tumors. Combined low scores for S-PD-L1
and T-PD-1 (PD Immunoscore) predicted a negative outcome for
all endpoints (DSS, DFS, and OS) in the total cohort and especially
in the SCC histologic subgroup. The ﬁnding was consistent in the
UNN and NH cohorts both and for all pathologic stages. The PD
Immunoscore was an independent prognostic factor in multivariate
analysis for DSS, DFS, and OS and remained so when adjusting for
S-CD8 and T-CD45RO.
The mechanisms regulating the expression of PD-L1 and PD-1
are incompletely understood. Particularly for PD-L1, the lack of
standardized assays is a major challenge in the assessment of its
predictive and prognostic role.26 Although its validity has recentlybeen challenged,20 the PD-L1 antibody applied in our study
(E1L3N) is commercially available, has been carefully validated by
us and others, and has been used in several NSCLC studies.27-32
Most clinical studies have used the proportion of membrane-
positive tumor cells as a cutoff for tumor positivity after it was
associated with the clinical response to anti-PD-1 therapy.33
However, the functional signiﬁcance of cytoplasmatic PD-L1
expression remains unclear, and it can be difﬁcult to distinguish
membranous from cytoplasmatic staining using IHC.32 Hence, we,
and others, have described and analyzed the combination of cyto-
plasmatic and membranous staining of PD-L1.29-31,34 Nevertheless,
it is important to be aware that IHC analysis can only capture a
snapshot in the dynamic nature of the antitumor response.
Although acceptable in primary tumor tissue, the frequency of
missing cores might have limited the statistical power of our analyses
of the metastatic LNs, and our results must be considered in light of
this. A heterogeneity of PD-L1 expression has been demonstrated in
NSCLC tumor tissue,20 and TMAs might underrepresent the het-
erogeneity. This was to some extent compensated for in the TMA
by the inclusion of 2 representative areas of tumor and 2 of stroma
from each tumor specimen. Also, we found a relatively high degree
of agreement between the cores from the same tumor. However, in
future validating studies, staining should also be performed of whole
tissue sections, because that is what is currently being used for
diagnostic purposes and also allows for further assessment of
heterogeneity.
We observed high tumor epithelial PD-L1 (T-PD-L1) in 26% of
patients, similar to recent studies using the same antibody29,31 in
patients with stage I-IIIA NSCLC. Numerous studies have reported a
wide range of NSCLC tumor cell PD-L1 positivity rates, and an
association with high T-PD-L1 has been reported for both poor30,34-37
and favorable29,38-41 outcomes. In contrast, other studies,27,31,42-44
including a recent meta-analysis,45 found no associations. Recently,
a Korean study reported no association between T-PD-L1 expres-
sion and OS in patients with SCC (n ¼ 331).31 In contrast, 1
German29 and 1 Australian39 study (SCC cohort sizes of 149 and
271, respectively) observed a positive prognostic effect, in line with
our ﬁndings. The heterogeneity with respect to assays, deﬁnitions of
positivity, and baseline characteristics such as ethnicity might
explain some of the differences.45 Smoking status, mutational load,
and oncogene driver mutation status seem to inﬂuence the activity
of PD-1 inhibitors in NSCLC patients.46,47 We found noClinical Lung Cancer Month 2016 - 11
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Immunoscore and smoking status. However, our data set did not
include an analysis of mutational status.
Although some reports have described the prevalence of PD-L1
expression in immune cells inﬁltrating stage I to IIIA NSCLC tu-
mors,20,28,48,49 we are the ﬁrst to describe the prognostic value of
stromal expression of PD-L1 (S-PD-L1). Although our method does
not allow for the distinction of stromal cell subtypes, morphologi-
cally, PD-L1þ stromal cells were consistent with immune cells.
Performing multiplexed IHC should clarify the signiﬁcance of
different subsets of stromal cells and would be of great interest in
future similar studies. We found high S-PD-L1 expression in 36%
of patients, which was signiﬁcantly associated with a positive
outcome in all patients and in the SCC subgroup, in particular. Our
ﬁndings contrast with the “adaptive immune resistance” as a major
immune evasion mechanism and supports the hypothesis that high
levels of S-PD-L1 induced by inﬂammatory mediators such as
interferon-g produced by immune cells reﬂect the presence of an
ongoing and, at least to some degree, functional tumor microenvi-
ronmental immune response. In line with this, Herbst et al50 found
immune cell expression of PD-L1 was predictive of the response to
antiePD-L1 treatment in patients with advanced NSCLC,
emphasizing the importance of pre-existing immunity that is further
ampliﬁed during treatment.
As the ﬁrst to assess PD-1 positivity in TILs in the intraepithelial
(T-PD-1) and stromal (S-PD-1) compartments separately, we
observed that high T-PD-1 expression was associated with improved
prognosis for all patients and particularly for the SCC histologic
subgroup. Three previous studies (2 Korean and 1 German) have
investigated PD-1, combined stromal and intraepithelial, in patients
with stage I to III NSCLC, using different assays and scoring
methods.29-31 The Korean studies found that PD-1þ TILs were
positively associated with OS in patients with SCC31 and with DFS
in patients with ADC.30 In contrast, the German investigators did
not observe any association with OS.29 Our results might reﬂect the
importance of previously activated immune cells inﬁltrating tumor
tissue and not residing solely around the outer edge, thus avoiding
“immunologic ignorance” and “excluded inﬁltrate,” 2 of the patterns
described in patients who don’t respond to anti-PD-L1 treatment.51
A novel ﬁnding in the present investigation was the lack of a
signiﬁcant association between survival and the expression of tumor
epithelial PD-L1 and intraepithelial PD-1þ TILs in LN metastasis
(n ¼ 143), regardless of the histologic subgroups, even when
multiple cutoffs were tested. We found the frequency of high T-PD-
L1 identical in Nþ LN and primary tumors, and the score was
maintained from primary tumor to LN metastasis in 69% of cases,
in line with the ﬁndings from a previous study.31 The frequency of
high T-PD-1 TILs was lower in Nþ LNs than in primary tumors;
38% of patients displayed a high score in the primary tumor and a
low score in the Nþ LNs. Others have found functional differences
in the immune inﬁltrates of primary tumors and metastatic sites and
indications of more tolerogenic and tumor-promoting microenvi-
ronments in metastatic LNs versus tumor-free LNs.52-54 Hence, our
study ﬁndings shed light on the differences in the characteristics of
the immune response in primary tumor and metastatic tissue,
although the limited Nþ study size reduced our ability to draw
conclusions. If conﬁrmed in larger studies, this ﬁnding supports thatClinical Lung Cancer Month 2016primary tissue samples, rather than samples from metastatic LNs,
should be used for analysis of these biomarkers in the prognostic
setting.
By combining the PD Immunoscore with the pathologic stage,
the stratiﬁcation of patient survival might be considerably improved
(Figure 3). Although the TNM classiﬁcation alone stratiﬁes patient
5-year DSS as 20% to 72% according to pathologic stage IIIA and I,
respectively, the addition of a PD Immunoscore increases the
stratiﬁcation of patient survival, ranging from 8% (pathologic stage
IIIA and PD Immunoscore “low þ low”) to 74% (pathologic stage I
and PD Immunoscore of “other score combinations”). For patients
with pathologic stage I, the 5-year DSS varied from 64% to 74%
according to the PD Immunoscore “low þ low” versus “other score
combinations”. For pathologic stage II, it varied from 34% to 63%
and for pathologic stage IIIA, from 8% to 31%. Thus, the PD
Immunoscore has the potential to stratify patients with regard to
survival even within each pathologic stage.
The retrospective nature of the present study introduced a po-
tential bias from variable diagnostic accuracy and treatment.
However, the PD Immunoscore was a signiﬁcant prognostic factor
independent of adjuvant chemotherapy or radiotherapy and of
whether patients were treated before or after the introduction of
adjuvant chemotherapy in accordance with the national recom-
mendations (2005; data not shown).
Measuring the expression of PD-1 and PD-L1 in the tumor
microenvironment might be of considerable clinical relevance,
representing facets of the immune response seen in “inﬂamed
cancers” versus “noninﬂamed cancers.” If conﬁrmed in prospective
studies, this type of prognostic stratiﬁcation might assist in the se-
lection of patients for adjuvant treatment and the choice of order
and type of treatment (eg, chemotherapy vs. immunotherapy). Also,
the PD Immunoscore could be tested as a predictor of anti-PD-
pathway treatment response in future studies.Conclusion
We attempted to predict the outcomes of patients with NSCLC
stage I to IIIA according to the PD-1 and PD-L1 expression levels in
primary tumors and metastatic LNs. We identiﬁed the density of
stromal PD-L1þ immune cells and intraepithelial PD-1þ TILs in
primary tumors as independent positive prognostic factors, mainly
attributed to the SCC subgroup. The combined low scores added
signiﬁcantly to the prognostic effect, revealing substantial differ-
ences in survival within each pathologic stage. The combination
remained an independent prognostic factor for DSS, DFS, and OS
for all patients, even after adjustment for immunologic markers with
strong independent prognostic effect. The evaluation of PD-1 and
PD-L1 expression in the tumor microenvironment, combined in a
novel Immunoscore approach to supplement the TNM classiﬁca-
tion in predicting patient prognosis, seems feasible. If conﬁrmed in
prospective studies, this could translate into changes in future
treatment decision-making.Clinical Practice Points
 For NSCLC patients, signiﬁcant differences in survival within
each TNM stage impede its prognostic accuracy, and novel
prognostic biomarkers are warranted.
Erna-Elise Paulsen et al Analysis of the presence and subtypes of TILs in the tumor
microenvironment supplement the prognostic yield of the TNM
classiﬁcation in other cancers and exploring an Immunoscore
concept in NSCLC is of great interest.
 Treatment targeting the immune checkpoint molecules PD-1 and
PD-L1 has proved effective in some NSCLC patients; however,
their potential prognostic value remains uncertain. Thus,
exploring the expression in both tumor epithelial cells and stromal
immune cells and the association with the outcomes is relevant.
 Our ﬁndings showed that a low density of PD-L1þ stromal
immune cells and PD-1þ intraepithelial TILs independently
predicted for unfavorable survival outcomes, especially for pa-
tients with SCC. Low scores for both of these 2 markers com-
bined (PD Immunoscore) independently predicted poor survival
(DSS, DFS, and OS) in patients with TNM stage I, II, and IIIA
resected NSCLC, allowing the stratiﬁcation of patient 5-year
DSS ranging from 8% to 74%.
 These results suggest that high expression of PD-L1 and PD-1
indicates the presence of an ongoing tumor microenvironment
immune response inﬂuencing patient survival. Evaluating their
expression in the tumor microenvironment might in the future
assist treatment decision-making by allowing individualized risk
stratiﬁcation and aiding in the selection of patients for adjuvant
treatment and choice of order and type of treatment.Acknowledgments
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Supplemental Figure 1 Antibody Validation. (A) Programmed Cell Death Protein 1 Ligand (PD-L1; Catalog No. 13684; Clone, E1L3N;
Cell Signaling Technology, Danvers, MA) and (B) Programmed Cell Death Protein 1 (PD-1; Catalog No.
ab52587; Clone, NAT105; Abcam, Cambridge, UK). Lanes 1 and 2, Molecular Weight Markers (1, SeeBlue; 2,
Magic Marker XP); Lane 3, Empty Vector (Catalog No. LY5000001/Negative Control); Lane 4, Transient
Overexpressed Human HEK293T Cell Lysates for PD-L1 (Catalog No. LY415473) and PD-1 (Catalog No.
LY401555). The Most Prominent Bands Represent the Observed Molecular Weight of the Detected Protein,
Which Corresponded Intimately With the Predicted Weight (PD-L1, 40-50 kDa; PD-1, 47 kDa) Provided by the
Manufacturer
Supplemental Figure 2 Programmed Cell Death Protein 1 (PD-1) and PD-1 Ligand (PD-L1) Immunohistochemistry in Metastatic Lymph
Nodes. Immunohistochemical Analysis of NoneSmall-Cell Lung Cancer Representing Different Scores for
Tumor Cell (T) and Stromal (S) Expression in Metastatic Lymph Nodes. (A) Low T-PD-1 Score (Squamous Cell
Carcinoma [SCC]). (B) High T-PD-1 Score (Adenocarcinoma [ADC]). (C) Low T-PD-L1 Score (SCC). (D) High
T-PD-L1 Score (ADC). Original Magniﬁcation 320
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Supplemental Table 1 Spearman Rank Correlations Between Mean Scores of PD-L1 and PD-1 in Tumor and Stromal Primary Tissue
and Lymph Node Tissue
Variable S-PD-L1 T-PD-L1 ND LN T-PD-L1 S-PD-1 T-PD-1 ND LN T-PD-1
S-PD-L1 e
T-PD-L1 .384a e
Nþ LN T-PD-L1 NS .232b e
S-PD-1 .354a .195a NS e
T-PD-1 .279a .113b NS .537a e
Nþ LN T-PD-1 NS NS NS NS .225b e
Abbreviations: Nþ LN ¼ metastatic lymph node; NS ¼ not signiﬁcant (P  .05); PD-1 ¼ programmed cell death protein 1; PD-1L ¼ PD-1 ligand; S ¼ stromal; T ¼ tumor.
aStatistically signiﬁcant (P < .001).
bStatistically signiﬁcant (P < .05).
Supplemental Table 2 Intraclass Correlations and Cohen’s Kappa Between Scorers for Investigated Prognostic Markers
Variable S-PD-L1 T-PD-L1 ND LN T-PD-L1 S-PD-1 T-PD-1 ND LN T-PD-1
ICC (A,2) 0.879 0.939 0.951 0.900 0.891 0.826
P value <.001 <.001 <.001 <.001 <.001 <.001
Kappa 0.563 0.754 0.742 0.602 0.582 0.593
P value <.001 <.001 <.001 <.001 <.001 <.001
Abbreviations: A,2 ¼ 2-way random effects model with absolute agreement; ICC ¼ intraclass correlation; Nþ LN ¼ metastatic lymph node; PD-1 ¼ programmed cell death protein 1; PD-1L ¼ PD-1
ligand; S ¼ stromal; T ¼ tumor.
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Supplemental Table 3 Prognostic Effect of Tumor Epithelial and Stromal PD-1 and PD-L1 Expression in Primary Tumors and Metastatic Lymph Nodes on Disease-Free Survival and Overall
Survival (Univariate Analyses; Log-Rank Test, Unadjusted Cox Proportional Hazard Ratios)
Variable
All Patients SCC ADC
n (%)
5-Year
Survival
(%)
Median
Survival
(mo) HR (95% CI) P Value n (%)
5-Year
Survival
(%)
Median
Survival
(mo) HR (95% CI) P Value n (%)
5-Year
Survival
(%)
Median
Survival
(mo) HR (95% CI) P Value
DFS
S-PD-L1 .039a .007a .710
High 182 (34) 59 87 1.00 105 (36) 77 229 1.00 67 (33) 36 36 1.00
Low 323 (60) 47 44 1.33 (1.01-1.74) 173 (60) 53 119 1.76 (1.16-2.68) 120 (60) 43 38
Missing 31 (6) 11 (4) 14 (7)
T-PD-L1 .470 .457 .389
High 130 (24) 54 65 1.00 64 (22) 72 178 1.00 55 (27) 40 41 1.00
Low 373 (70) 51 68 1.11 (0.84-1.47) 211 (73) 60 NR 0.84 (0.53-1.33) 131 (65) 39 33 1.19 (0.80-1.87)
Missing 33 (6) 14 (5) 15 (8)
Nþ LN T-PD-L1 .461 .278 .374
High 35 (25) 33 15 1.00 15 (20) 46 15 1.00 17 (29) 29 18 1.00
Low 84 (59) 31 15 1.15 (0.72-1.84) 47 (64) 42 22 1.36 (0.65-2.83) 30 (52) 17 13 0.73 (0.36-1.47)
Missing 23 (16) 12 (16) 11 (19)
S-PD-1 .043a .138 .202
High 253 (47) 56 83 1.00 134 (46) 69 229 1.00 98 (49) 43 43 1.00
Low 253 (47) 47 42 1.29 (1.01-1.66) 142 (49) 55 178 1.33 (0.91-1.95) 90 (45) 37 31 1.28 (0.88-1.86)
Missing 30 (6) 13 (5) 13 (6)
T-PD-1 .021a .007a .466
High 282 (53) 57 119 1.00 155 (54) 71 229 1.00 103 (51) 44 40 1.00
Low 225 (42) 45 41 1.34 (1.04-1.72) 122 (42) 51 65 1.68 (1.15-2.45) 85 (42) 34 33 1.15 (0.79-1.67)
Missing 29 (5) 12 (4) 13 (7)
Nþ LN T-PD-1 .763 .267 .686
High 38 (27) 34 13 1.00 14 (19) 58 105 1.00 20 (35) 21 11 1.00
Low 87 (61) 30 15 0.90 (0.56-1.44) 48 (65) 41 15 0.51 (0.20-1.32) 34 (59) 19 18 1.14 (0.60-2.16)
Missing 17 (12) 12 (16) 4 (7)
S-PD-L1 þ T-PD-1 <.001a <.001a .174
Other 339 (63) 58 119 1.00 195 (68) 71 229 1.00 117 (58) 44 44 1.00
Low þ low 157 (29) 37 28 1.65 (1.28-2.14) 78 (27) 40 26 2.04 (1.38-3.01) 68 (34) 32 31 1.31 (0.89-1.92)
Missing 40 (8) 16 (5) 16 (8)
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Supplemental Table 3 Continued
Variable
All Patients SCC ADC
n (%)
5-Year
Survival
(%)
Median
Survival
(mo) HR (95% CI) P Value n (%)
5-Year
Survival
(%)
Median
Survival
(mo) HR (95% CI) P Value n (%)
5-Year
Survival
(%)
Median
Survival
(mo) HR (95% CI) P Value
Overall survival
S-PD-L1 .053 .085 .344
High 182 (34) 52 70 1.00 105 (36) 58 78 1.00 67 (33) 44 52 1.00
Low 323 (60) 40 40 1.24 (1.00-1.54) 173 (60) 43 33 1.29 (0.96-1.72) 120 (60) 36 45 1.44 (1.19-1.70)
Missing 31 (6) 11 (4) 14 (7)
T-PD-L1 .136 .064 .530
High 130 (24) 51 62 1.00 64 (22) 61 84 1.00 55 (27) 44 47 1.00
Low 373 (70) 43 45 1.20 (0.94-1.53) 211 (73) 45 40 1.37 (0.98-1.92) 131 (65) 38 50 1.13 (0.77-1.67)
Missing 33 (6) 14 (5) 15 (8)
Nþ LN T-PD-L1 .804 .853 .180
High 35 (25) 27 19 1.00 15 (20) 33 19 1.00 17 (29) 25 37 1.00
Low 84 (59) 20 17 1.06 (0.69-1.60) 47 (64) 25 18 0.95 (0.52-1.72) 30 (52) 9 15 1.58 (0.81-3.09)
Missing 23 (16) 12 (16) 11 (19)
S-PD-1 .279 .089 .747
High 253 (47) 47 57 1.00 134 (46) 54 71 1.00 98 (49) 41 52 1.00
Low 253 (47) 41 41 1.12 (0.91-1.37) 142 (49) 43 33 1.27 (0.96-1.68) 90 (45) 37 45 1.06 (0.75-1.48)
Missing 30 (6) 13 (5) 13 (6)
T-PD-1 .027a .052 .359
High 282 (53) 49 57 1.00 155 (54) 55 71 1.00 103 (51) 43 47 1.00
Low 225 (42) 38 36 1.22 (0.80-1.86) 122 (42) 41 31 1.13 (1.00-1.73) 85 (42) 34 47 1.17 (0.85-1.64)
Missing 29 (5) 12 (4) 13 (7)
Nþ LN T-PD-1 .358 .554 .659
High 38 (27) 26 19 1.00 14 (19) 36 35 1.00 20 (34) 15 12 1.00
Low 87 (61) 21 17 1.18 (0.82-1.70) 48 (65) 29 15 1.21 (0.64-2.32) 34 (59) 11 15 1.15 (0.62-2.11)
Missing 17 (12) 12 (16) 4 (7)
S-PD-L1 þ T-PD-1 .002a .019a .071
Other 339 (63) 50 59 1.00 195 (68) 54 71 1.00 117 (58) 46 54 1.00
Low þ low 157 (29) 32 31 1.40 (1.13-1.73) 78 (27) 35 26 1.42 (1.06-1.90) 68 (34) 27 41 1.37 (0.97-1.94)
Missing 40 (8) 16 (5) 16 (8)
Abbreviations: CI ¼ conﬁdence interval; HR ¼ hazard ratio; Nþ LN ¼ metastatic lymph node; NR ¼ not reached; PD-1 ¼ programmed cell death protein 1; PD-1L ¼ PD-1 ligand; S ¼ stromal; T ¼ tumor.
aStatistically signiﬁcant.
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Supplemental Table 4 Results of Cox Regression Analysis Summarizing Signiﬁcant Independent Prognostic Factors for Disease-Free
Survival and Overall Survival
Variable
All Patients SCC ADC
HR (95% CI) P Value HR (95% CI) P Value HR (95% CI) P Value
Disease-free survival
Clinicopathologic variablesa
Pathologic stage <.001b,c <.001b,c <.001b
I 1.00 1.00 1.00
II 1.67 (1.26-2.14) <.001b 1.85 (1.21-2.83) .004b 2.05 (1.34-3.12) .001b
IIIA 3.35 (2.39-4.70) <.001b 5.36 (3.17-9.06) <.001b 2.98 (1.82-4.90) <.001b
Histologic type <.001b,c
SCC 1.00
ADC 1.81 (1.38-2.38) <.001b
LCC 1.51 (0.97-2.36) .069
Vascular inﬁltration
No vs. yes 1.44 (1.06-1.95) .019b 1.46 (0.94-2.27) .092 1.33 (0.81-2.19) .264
Differentiation .016b,c NE .012b,c
Well 1.00 1.00
Moderate 1.81 (1.11-2.94) .017b 2.45 (1.29-4.64) .006b
Poor 2.04 (1.26-3.32) .004b 2.58 (1.36-4.89) .004b
Sex
Female vs. male NE NE NE
ECOG PS .004b,c NE <.001b,c
0 1.00 1.00
1 1.50 (1.16-1.93) .002b 1.73 (1.18-2.55) .005b
2 1.65 (0.96-2.84) .068 4.83 (2.25-10.39) <.001b
Smoking NE NE NE
Never
Present
Former
Surgical margins
Free vs. not free NE NE 1.26 (0.62-2.59) .522
PD variables assessed in
separate modelsd
T-PD-L1
High vs. low 0.91 (0.68-1.22) .522 1.12 (0.71-1.76) .640 0.99 (0.65-1.51) .967
S-PD-L1
High vs. low 1.24 (0.95-1.63) .118 1.80 (1.19-2.74) .006b 0.88 (0.59-1.32) .542
T-PD-1
High vs. low 1.41 (1.09-1.81) .009b 1.94 (1.32-2.87) .001b 1.40 (0.94-2.07) .096
S-PD-L1 þ T-PD-1
Other scores vs. low þ low 1.57 (1.21-2.05) .001b 2.20 (1.49-3.26) <.001b 1.39 (0.93-2.07) .104
PD variables assessed in the
same modeld
S-PD-L1a
High vs. low 1.20 (0.91-1.58) .204 1.71 (1.12-2.61) .013b 0.77 (0.51-1.18) .232
T-PD-1a
High vs. low 1.42 (1.10-1.84) .007b 1.83 (1.24-2.71) .002b 1.44 (0.97-2.14) .073
PD Immunoscore assessed with S-CD8
and T-CD45ROd
S-PD-L1 þ T-PD-1a
Other scores vs. low þ low 1.34 (1.01-1.77) .040b 1.73 (1.14-2.63) .010b 1.24 (0.81-1.90) .327
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Supplemental Table 4 Continued
Variable
All Patients SCC ADC
HR (95% CI) P Value HR (95% CI) P Value HR (95% CI) P Value
S-CD8aS-CD8a
High vs. low 1.50 (1.14-1.96) .003b 1.68 (1.12-2.54) .013b 1.48 (1.00-2.57) .051
T-CD45ROa
High vs. low 1.40 (1.04-1.88) .025b 1.55 (1.01-2.39) .045b 0.86 (0.53-1.39) .528
Overall survival
Clinicopathologic variablesa
Pathologic stage <.001b,c <.001b,c <.001b,c
I 1.00 1.00 1.00
II 1.12 (0.90-1.40) .318 1.26 (0.94-1.70) .118 1.48 (1.00-2.20) .051
IIIA 2.73 (2.07-3.59) <.001b 2.91 (1.96-4.32) <.001b 3.04 (1.97-4.69) <.001b
Histologic type NE
SCC
ADC
LCC
Vascular inﬁltration
No vs. yes 1.71 (1.32-2.23) <.001b 1.46 (1.04-2.05) .029b 1.76 (1.11-2.80) .017b
Differentiation NE NE .257c
Well 1.00
Moderate 1.44 (0.87-1.29) .156
Poor 1.62 (1.14-2.30) .107
Sex
Female vs. male 1.53 (1.22-1.93) <.001b NE 1.69 (1.20-2.40) .003b
ECOG PS <.001b,c NE <.001b,c
0 1.00 1.00
1 1.33 (1.08-1.64) .008b 1.31 (0.92-1.87) .140
2 2.16 (1.46-3.18) <.001b 3.87 (2.01-7.48) <.001b
Age
65 year vs. >65 year 1.52 (1.24-1.88) <.001b 1.73 (1.29-2.32) <.001b NE
Surgical margins
Free vs. not free NE NE NE
PD variables assessed in separate modelsd
T-PD-L1
High vs. low 1.14 (0.98-1.46) .277 1.35 (0.96-1.89) .085 1.30 (0.87-1.96) .200
S-PD-L1
High vs. low 1.19 (0.96-1.48) .123 1.26 (0.94-1.69) .117 1.19 (0.83-1.71) .346
T-PD-1
High vs. low 1.25 (1.02-1.54) .032b 1.37 (1.04-1.81) .027b 1.24 (0.88-2.13) .213
S-PD-L1 þ T-PD-1
Other scores vs. low þ low 1.36 (1.10-1.69) .005b 1.48 (1.10-1.99) .010b 1.41 (0.99-1.99) .055
PD variables assessed in same modeld
S-PD-L1a
High vs. low 1.18 (0.95-1.47) .144 1.23 (0.92-1.65) .167 1.15 (0.79-1.68) .462
T-PD-1a
High vs. low 1.27 (1.03-1.56) .026b 1.37 (1.03-1.81) .029b 1.28 (0.90-1.80) .165
PD Immunoscore assessed with S-CD8
and T-CD45ROd
S-PD-L1 þ T-PD-1a
Other scores vs. low þ low 1.26 (1.01-1.58) .044b 1.27 (0.93-1.73) .140 1.42 (1.00-2.02) .047b
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Supplemental Table 4 Continued
Variable
All Patients SCC ADC
HR (95% CI) P Value HR (95% CI) P Value HR (95% CI) P Value
S-CD8a
High vs. low 1.32 (1.06-1.65) .013b 1.67 (1.25-2.39) <.001b 1.05 (0.71-1.56) .795
T-CD45ROa
High vs. low 1.39 (1.09-1.78) .009b 1.58 (1.14-2.19) .006b 1.09 (0.72-1.66) .687
Abbreviations: ADC ¼ adenocarcinoma; CI ¼ conﬁdence interval; ECOG ¼ Eastern Cooperative Oncology Group; HR ¼ hazard ratio; LCC ¼ large cell carcinoma; NE ¼ not entered;
PD-1 ¼ programmed cell death protein 1; PD-1L ¼ PD-1 ligand; PS ¼ performance status; SCC ¼ squamous cell carcinoma; S ¼ stromal; T ¼ tumor.
aIn the same model.
bStatistcally signiﬁcant.
cOverall signiﬁcance as a prognostic factor.
dAll clinicopathologic covariates signiﬁcant in multivariate analysis were included in each model.
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Supplemental Table 5 Prognostic Impact of S-CD8 and T-CD45RO on Disease-Speciﬁc Survival, Disease-Free Survival, and Overall Survival (Univariate Analyses; Log-Rank Test, Unad-
justed Cox Proportional Hazard Ratios)
Variable
All Patients SCC ADC
n (%)
5-Year
Survival
(%)
Median
Survival
(mo) HR (95% CI) P Value n (%)
5-Year
Survival
(%)
Median
Survival
(mo) HR (95% CI) P Value n (%)
5-Year
Survival
(%)
Median
Survival
(mo) HR (95% CI) P Value
DSS
S-CD8 <.001a <.001a .160
High 306 (57) 66 235 1.00 163 (56) 77 235 1.00 117 (58) 52 76 1.00
Low 212 (40) 46 51 1.73 (1.32-2.27) 118 (41) 49 44 2.23 (1.49-3.35) 77 (38) 41 50 1.34 (0.89-2.01)
MD 18 (3) 8 (3) 7 (4)
T-CD45RO .002a <.001a .636
High 371 (69) 60 189 1.00 201 (70) 72 235 1.00 141 (70) 47 57 1.00
Low 133 (25) 47 50 1.61 (1.19-2.16) 71 (25) 44 35 2.32 (1.52-3.56) 50 (25) 51 71 1.12 (0.70-1.80)
MD 32 (6) 17 (6) 10 (5)
DFS
S-CD8 <.001a <.001a .099
High 306 (57) 60 124 1.00 163 (56) 74 229 1.00 117 (58) 45 41 1.00
Low 212 (40) 39 29 1.62 (1.26-2.08) 118 (41) 45 29 2.00 (1.37-2.92) 77 (38) 30 31 1.37 (0.94-1.99)
MD 18 (3) 8 (3) 7 (4)
T-CD45RO .001a <.001a .786
High 371 (69) 54 85 1.00 201 (70) 79 229 1.00 141 (70) 40 33 1.00
Low 133 (25) 38 28 1.58 (1.20-2.08) 71 (25) 41 26 2.10 (1.40-3.14) 50 (25) 37 42 1.06 (0.69-1.64)
MD 32 (6) 17 (6) 10 (5)
OS
S-CD8 <.001a <.001a .550
High 306 (57) 51 64 1.00 163 (56) 58 83 1.00 117 (58) 43 54 1.00
Low 212 (40) 36 32 1.44 (1.18-1.77) 118 (41) 36 25 1.74 (1.32-2.29) 77 (38) 34 44 1.11 (0.79-1.56)
MD 18 (3) 8 (3) 7 (4)
T-CD45RO <.001a <.001a .163
High 371 (69) 47 54 1.00 201 (70) 54 71 1.00 141 (70) 40 49 1.00
Low 133 (25) 34 28 1.54 (1.23-1.95) 71 (25) 29 24 1.79 (1.31-2.45) 50 (25) 38 33 1.31 (0.90-1.92)
MD 32 (6) 17 (6) 10 (5)
Abbreviations: ADC ¼ adenocarcinoma; CI ¼ conﬁdence interval; DFS ¼ disease-free survival; DSS ¼ disease-speciﬁc survival; HR ¼ hazard ratio; MD ¼ missing data; Nþ LN ¼ metastatic lymph node; NR¼ not reached; OS¼ overall survival; S ¼ stromal; SCC ¼ squamous
cell carcinoma; T ¼ tumor.
aStatistically signiﬁcant.
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